Cover Image
市場調查報告書

Lumosa Therapeutics Co., Ltd.:產品平台分析

Lumosa Therapeutics Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 321996
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Lumosa Therapeutics Co., Ltd.:產品平台分析 Lumosa Therapeutics Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年12月24日 內容資訊: 英文 24 Pages
簡介

Lumosa Therapeutics Co., Ltd.(原SunTen Phytotech Co., Ltd.)是致力於開發解決未滿足醫療需求用之新治療藥的生物科技企業。該公司的產品活用於神經疾病,高血壓,糖尿病足部潰傷,腫瘤,發炎性疾病等領域。

本報告提供Lumosa Therapeutics Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Lumosa Therapeutics Co., Ltd.的基本資料

Lumosa Therapeutics Co., Ltd.概要

  • 主要資訊
  • 企業資料

Lumosa Therapeutics Co., Ltd. :R&D概要

  • 主要的治療範圍

Lumosa Therapeutics Co., Ltd. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Lumosa Therapeutics Co., Ltd. :開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Lumosa Therapeutics Co., Ltd. :藥物簡介

  • LT-1001
  • STD-07
  • LT-2001
  • LT-3001
  • STD-06

Lumosa Therapeutics Co., Ltd. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Lumosa Therapeutics Co., Ltd. :暫停中的計劃

Lumosa Therapeutics Co., Ltd. :總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC06751CDB

Summary

Global Markets Direct's, 'Lumosa Therapeutics Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Lumosa Therapeutics Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lumosa Therapeutics Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Lumosa Therapeutics Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Lumosa Therapeutics Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Lumosa Therapeutics Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Lumosa Therapeutics Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Lumosa Therapeutics Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Lumosa Therapeutics Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Lumosa Therapeutics Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lumosa Therapeutics Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Lumosa Therapeutics Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lumosa Therapeutics Co., Ltd. Snapshot
    • Lumosa Therapeutics Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Lumosa Therapeutics Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Lumosa Therapeutics Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lumosa Therapeutics Co., Ltd. - Pipeline Products Glance
    • Lumosa Therapeutics Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Lumosa Therapeutics Co., Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Lumosa Therapeutics Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Lumosa Therapeutics Co., Ltd. - Drug Profiles
    • LT-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STD-07
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-3001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STD-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lumosa Therapeutics Co., Ltd. - Pipeline Analysis
    • Lumosa Therapeutics Co., Ltd. - Pipeline Products by Target
    • Lumosa Therapeutics Co., Ltd. - Pipeline Products by Route of Administration
    • Lumosa Therapeutics Co., Ltd. - Pipeline Products by Molecule Type
    • Lumosa Therapeutics Co., Ltd. - Pipeline Products by Mechanism of Action
  • Lumosa Therapeutics Co., Ltd. - Dormant Projects
  • Lumosa Therapeutics Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lumosa Therapeutics Co., Ltd., Key Information
  • Lumosa Therapeutics Co., Ltd., Key Facts
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Indication, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Stage of Development, 2014
  • Lumosa Therapeutics Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Lumosa Therapeutics Co., Ltd. - Phase III, 2014
  • Lumosa Therapeutics Co., Ltd. - Phase I, 2014
  • Lumosa Therapeutics Co., Ltd. - Preclinical, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Target, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Route of Administration, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Molecule Type, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Lumosa Therapeutics Co., Ltd. - Dormant Developmental Projects,2014

List of Figures

  • Lumosa Therapeutics Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Stage of Development, 2014
  • Lumosa Therapeutics Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Top 10 Target, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Lumosa Therapeutics Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top